Ben Tran
YOU?
Author Swipe
View article: 50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study
50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study Open
Background Immune checkpoint inhibitor (ICI)-based regimens, represent the current standard of care for first line (1 L) metastatic renal cell carcinoma (mRCC). A subset of patients (pts) experience progressive disease (PD) on first restag…
View article: Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey Open
Background Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothelial carcinoma (aUC), based on its superior efficacy over platinum-based chemotherapy. As this…
View article: Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019
Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019 Open
There is a need to raise awareness of testicular cancer in high-risk geographical areas and age groups, and to conduct further research into drivers of localised spatial patterns.
View article: Karyotyping and prenatal diagnosis of trisomy 8 mosaicism
Karyotyping and prenatal diagnosis of trisomy 8 mosaicism Open
Background: Trisomy 8 mosaicism (T8M) is associated with a wide phenotypic spectrum ranging from mild dysmorphism to severe congenital anomalies. We report a case involving a 31-year-old pregnant woman diagnosed with T8M via amniocentesis …
View article: Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours
Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours Open
Background Standard of care (SOC) treatments for International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis stage II germ cell tumours (GCT) involve primary orchidectomy followed by combination chemotherapy for both seminom…
View article: Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours
Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours Open
Background Testicular germ cell tumours (TGCTs) are amongst the most common malignancies in young men, and their incidence is increasing worldwide. Tissue heterogeneity hampers efforts to understand how TGCT precursors (termed germ cell ne…
View article: Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series Open
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [177Lu]…
View article: The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database
The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database Open
Prostate cancer is a common malignancy with an increasing incidence in ageing populations. However, older patients with prostate cancer are often underrepresented in traditional clinical trials. The electronic Prostate Cancer Australian an…
View article: Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CTX131 construct
View article: Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Summary of Treatment-Related TEAEs in Safety Analysis Set by Dose Level
View article: Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Flow Cytometry Antibody Panel
View article: Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CTX130 construct
View article: Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Cytokine secretion during CAR T-cell activation upon coculture with CD70+ RCC cells
View article: Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Cytokine secretion during CAR T-cell activation upon coculture with CD70+ RCC cells
View article: Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Flow Cytometry Antibody Panel
View article: Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Summary of Treatment-Related TEAEs in Safety Analysis Set by Dose Level
View article: Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CTX131 construct
View article: Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CONSORT flow diagram for COBALT-RCC trial design schematic
View article: Supplementary Figure S5 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S5 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
COBALT-RCC trial design schematic
View article: Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CTX130 construct
View article: Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
CONSORT flow diagram for COBALT-RCC trial design schematic
View article: Supplementary Figure S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Supplementary Figure S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma Open
Tumor biopsy CD70 H-scores